Complete Story
 

XOSPATA Is the First FDA-Approved FLT3 Inhibitor Indicated for Patients with Relapsed or Refractory FLT3m+ Acute Myeloid Leukemia (AML)1

Click here to learn more. 

Printer-Friendly Version